Article
New polycomb group protein enhancer of zeste homolog (EZH) 2-derived peptide with the potential to induce cancer-reactive cytotoxic T lymphocytes in prostate cancer patients with HLA-A3 supertype alleles.
International immunopharmacology - 1 May 2015
Minami Takafumi, Minami Tomoko, Shimizu Nobutaka, Yamamoto Yutaka, De Velasco Marco A, Nozawa Masahiro, Yoshimura Kazuhiro, Harashima Nanae, Harada Mamoru, Uemura Hirotsugu
Abstract excerpt
Analyses on reactivity of anti-cancer cytotoxic T lymphocytes (CTLs) and clinical application of peptide-based anti-cancer vaccine have been mainly focused on patients with HLA-A2 or -A24 alleles. In this study, we identified an enhancer of zeste homolog (EZH) 2-derived peptide applicable for ant...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.